Our mission is developing new efficacious universal protein subunit vaccines for infectious agents that are a major public health concern worldwide, and novel diagnostics for both infectious and neuro-degenerative diseases. 

Our underlying proprietary technologies are derived from a revolutionary proteome mining platform for protein-antigen discovery called Proteomics-based Expression Library Screening (PELS).  This technology was developed at Massachusetts General Hospital / Harvard Medical School by our founder.

Our current focus is on human diarrheal pathogens, biothreat agents, veterinary infectious agents, and neurodegenertive diseases, such as Parkinson's Disease (PD) and Alzheimer's Disease (AD).  

PathoVacs is seeking collaborations for commercialization of our current vaccine targets .  In addition, PathoVacs provides contract protein biomarker discovery services for a broad array of pathogens.